Rifaximin Treatment of Papulopustular Rosacea



Status:Completed
Conditions:Cosmetic
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - Any
Updated:5/3/2014
Start Date:April 2013
End Date:December 2014
Contact:Martin Steinhoff, MD, Ph.D.
Email:steinhoffm@derm.ucsf.edu
Phone:415-885-7622

Use our guide to learn which trials are right for you!

Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study

The purpose of this study is to determine the effects of rifaximin on skin symptoms in
patients with rosacea by double-blinded, placebo-controlled, crossover study.

100 patients will be randomized into two groups.

Group A will receive one rifaximin 550 mg tablet three times a day (1650 mg/day) for 14
days, and after a 4-week washout period, receive one placebo tablet three times a day for 14
days.

Group B will receive placebo first, and then rifaximin with the same dosage schedule to
Group A.

Assessments will be performed before application and 4 weeks after the last dosage, for both
of rifaximin and placebo.

Inclusion Criteria:

- Males and females

- > 18 years of age with rosacea defined as:

- 3-40 papules/pustules and < 2 nodules,

- A score of 2-4 on the Investigator Global Assessment

Exclusion Criteria:

- Untreated pancreatic insufficiency

- Crohn's disease

- Ulcerative colitis

- Active celiac disease by clinical history

- End stage renal failure

- Less than 18 years old

- Pregnancy or positive pregnancy test

- Rosacea subtype 1 (no papules )

- Topical or oral antibiotics within 4 weeks

- Acne treatments within 4 weeks prior to randomization

- Systemic retinoids within 90 days

- Topical or systemic corticosteroids 4 weeks prior to randomization
We found this trial at
1
site
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials